1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NovoCure Limited
  6. Company
    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
Real-time Estimate Cboe BZX  -  10:52 2022-06-28 am EDT
74.76 USD   +0.09%
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination to Treat Lung Cancer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo NovoCure Limited
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Number of employees : 1 167 people.
Sales per Business
20202021Delta
Tumor Treating Fields494.37100%535.03100% +8.23%
USD in Million
Sales per region
20202021Delta
United States340.7868.9%353.1166% +3.62%
Germany93.2618.9%93.9417.6% +0.72%
Japan29.085.9%34.646.5% +19.14%
Other EMEA18.653.8%30.585.7% +63.92%
Greater China12.592.5%22.774.3% +80.82%
USD in Million
Managers
Name Title Age Since
Asaf Danziger Chief Executive Officer & Director 55 2002
Ashley Cordova Chief Financial Officer 42 2020
Uri Weinberg Chief Science Officer - -
Ely Benaim Chief Medical Officer 60 2019
Wilhelmus Groenhuysen Chief Operating Officer - 2020
Ingrid Goldberg Investor Relations Contact - 2021
Frank Leonard Chief Development Officer - 2020
Pritesh Shah, Dr. Senior Vice President 44 2012
Gabrielle Fernandes Senior Director-Global Business Integration - 2021
Barak Ben Arye General Counsel - 2022
Members of the board
Name Title Age Since
William Doyle Executive Chairman 58 2016
Kin Yip Leung Vice Chairman 59 2011
William Vernon Lead Independent Director 65 -
Martin J. Madden Independent Director 61 2017
David T. Hung, Dr. Independent Director 63 2018
Jeryl Lynn Hilleman Independent Director 63 2018
Timothy Scannell Independent Director 56 2021
Asaf Danziger Chief Executive Officer & Director 55 2002
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 104,586,094 90,487,581 86.5% 0 0.0% 86.5%
Shareholders
NameEquities%
Capital Research & Management Co. (World Investors) 12,650,643 12.1%
Capital Research & Management Co. (International Investors) 11,345,026 10.8%
Capital Research & Management Co. (Global Investors) 11,082,364 10.6%
Baillie Gifford & Co. 9,340,845 8.93%
Hansj÷rg Wyss 8,141,397 7.78%
The Vanguard Group, Inc. 7,799,564 7.46%
Fidelity Management & Research Co. LLC 6,285,056 6.01%
Gert Lennart Perlhagen 4,501,700 4.30%
SSgA Funds Management, Inc. 2,498,569 2.39%
T. Rowe Price Associates, Inc. (Investment Management) 2,113,151 2.02%
Company contact information
NovoCure Ltd.
No. 4 The Forum
Grenville Street
2nd Floor
St. Helier, Jersey JE2 4UF

Phone : +44.15.3475.6700
Web : http://www.novocure.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of NovoCure Limited